Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INZY Inozyme Pharma

Not Yet Opened 03-18 16:00:00 EDT

0.9736

-0.0464

-4.55%

盘后0.9736

+0.00000.00%

18:47 EDT

High1.04	Low0.9201	Vol461.54K
Open1.01	D1 Closing1.02	Amplitude11.36%
Mkt Cap62.54M	Tradable Cap34.92M	Total Shares64.24M
T/O450.12K	T/O Rate1.29%	Tradable Shares35.86M
P/B1.08	ROE-102.90%	EPS-1.62
52wk High7.80	52wk Low0.9201	P/E-0.60
Dividend0.00	Div.Yield0.00	ROA-40.13%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"INZY","market":"US","secType":"STK","nameCN":"Inozyme Pharma","latestPrice":0.9736,"timestamp":1742328000000,"preClose":1.02,"halted":0,"volume":461538,"hourTrading":{"tag":"盘后","latestPrice":0.9736,"preClose":0.9736,"latestTime":"18:47 EDT","volume":5058,"amount":4927.7644,"timestamp":1742338076744},"delay":0,"floatShares":35862071,"shares":64240198,"eps":-1.62428,"marketStatus":"Not Yet Opened","change":-0.0464,"latestTime":"03-18 16:00:00 EDT","open":1.01,"high":1.036,"low":0.9201,"amount":450121.3037244,"amplitude":0.113627,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.62428,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742371200000},"marketStatusCode":0,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.04,"preClose":1.02,"latestTime":"09:25 EDT","volume":130,"amount":133.575793,"timestamp":1742304313258},"postHourTrading":{"tag":"盘后","latestPrice":0.9736,"preClose":0.9736,"latestTime":"18:47 EDT","volume":5058,"amount":4927.7644,"timestamp":1742338076744},"volumeRatio":0.684058,"impliedVol":1.3651,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/INZY","defaultTab":"news","newsList":[{"id":"2518771277","title":"Inozyme Pharma Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2518771277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518771277?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:18","pubTimestamp":1741691880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 07:18 ET (11:18 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2518714302","title":"Inozyme Pharma Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518714302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518714302?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:51","pubTimestamp":1741690260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 06:51 ET (10:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2518875984","title":"Inozyme Pharma Focuses on ENPP1 Deficiency Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2518875984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518875984?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 11:58","pubTimestamp":1741665529,"startTime":"0","endTime":"0","summary":"Inozyme Pharma, Inc. ( ($INZY) ) has released its Q4 earnings. Here is a breakdown of the information Inozyme Pharma, Inc. presented to its investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inozyme-pharma-focuses-on-enpp1-deficiency-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inozyme-pharma-focuses-on-enpp1-deficiency-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2518077192","title":"Analysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518077192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518077192?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 03:50","pubTimestamp":1741636209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inozyme Pharma (INZY – Research Report) and Urogen P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inozyme-pharma-inzy-and-urogen-pharma-urgn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inozyme-pharma-inzy-and-urogen-pharma-urgn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INZY","BK4139","BK4137","HCSG","URGN"],"gpt_icon":0},{"id":"2518277017","title":"Inozyme Pharma Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277017?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 00:33","pubTimestamp":1741624434,"startTime":"0","endTime":"0","summary":"Inozyme Pharma Inc reports results for the quarter ended December 31 - Earnings SummaryInozyme Pharma Inc INZY.OQ reported a quarterly adjusted loss of 41 cents per share for the quarter ended Decembe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2518274668","title":"Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518274668?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:39","pubTimestamp":1741621152,"startTime":"0","endTime":"0","summary":"Inozyme Pharma (INZY) has an average rating of Buy and mean price target of $18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INZY"],"gpt_icon":0},{"id":"2518279458","title":"Inozyme Pharma Inc : Wedbush Cuts Target Price to $7 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518279458?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:18","pubTimestamp":1741619893,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT14C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2518022528","title":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2518022528","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518022528?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:36","pubTimestamp":1741610169,"startTime":"0","endTime":"0","summary":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44217803/inozyme-pharma-fy-2024-gaap-eps-1-62-misses-1-60-estimate-co-prioritizes-activities-to-support-pl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2518722510","title":"Inozyme Pharma Inc - Expects $1.8 Million Cost for Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2518722510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518722510?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:33","pubTimestamp":1741609994,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2518408225","title":"Inozyme Pharma Inc - Cash and Cost Savings Expected to Support Operations Into Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2518408225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518408225?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:33","pubTimestamp":1741609994,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2518722561","title":"Inozyme Pharma FY EPS USD -1.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2518722561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518722561?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:30","pubTimestamp":1741609800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXB26038:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2518225676","title":"Inozyme Pharma FY Operating Expenses USD 104.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225676?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:30","pubTimestamp":1741609800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXB26038:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2518225119","title":"Press Release: Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225119","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225119?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:30","pubTimestamp":1741609800,"startTime":"0","endTime":"0","summary":"Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights. - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 -. \"The strategic refocusing of our portfolio necessitated difficult decisions, including a reduction in our workforce. These organizational changes, while challenging, are essential to extend our operational runway and maximize our ability to advance INZ-701 as a potential treatment for patients with ENPP1 Deficiency,\" continued Dr. Tre","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2517438551","title":"Inozyme Pharma Inc  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438551?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:27","pubTimestamp":1741354040,"startTime":"0","endTime":"0","summary":"Inozyme Pharma Inc  expected to post a loss of41cents a share - Earnings Preview Inozyme Pharma Inc INZY.OQ INZY.O is expected to show no change in quarterly revenue when it reports  results on March ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2513729771","title":"Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729771?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  24, 2025  (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare dis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031146/0/en/Inozyme-Pharma-to-Present-at-the-TD-Cowen-45th-Annual-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","INZY","COWN","TD","BK4139","BK4566","BK4207","BK4127"],"gpt_icon":0},{"id":"2513298869","title":"Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513298869","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513298869?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 21:30","pubTimestamp":1740144600,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  21, 2025  (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/21/3030451/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-at-CHOP-Cardiology-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2503058918","title":"Inozyme Pharma Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2503058918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503058918?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 23:25","pubTimestamp":1736781900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 10:25 ET (15:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2502802661","title":"Inozyme Pharma: Promising Pipeline and Market Potential Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2502802661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502802661?lang=en_us&edition=full_marsco","pubTime":"2025-01-11 23:38","pubTimestamp":1736609923,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/inozyme-pharma-promising-pipeline-and-market-potential-supports-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/inozyme-pharma-promising-pipeline-and-market-potential-supports-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INZY"],"gpt_icon":0},{"id":"2502804793","title":"Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502804793","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502804793?lang=en_us&edition=full_marsco","pubTime":"2025-01-11 23:30","pubTimestamp":1736609437,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inozyme Pharma (INZY – Research Report) and Intellia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inozyme-pharma-inzy-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inozyme-pharma-inzy-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4556","BK4137","BK4535","INZY","LU1861559042.SGD","NTLA","BK4585","BK4588","BK4139","HCSG"],"gpt_icon":0},{"id":"2502819853","title":"Positive Outlook for Inozyme Pharma Amidst Pipeline Advancements and Undervaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2502819853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502819853?lang=en_us&edition=full_marsco","pubTime":"2025-01-11 03:15","pubTimestamp":1736536519,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer has maintained their bullish stance on INZY stock, giving a Buy rating on January 8. Joseph Stringer has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-inozyme-pharma-amidst-pipeline-advancements-and-undervaluation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-inozyme-pharma-amidst-pipeline-advancements-and-undervaluation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INZY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inozyme.com","stockEarnings":[{"period":"1week","weight":-0.0377},{"period":"1month","weight":-0.2555},{"period":"3month","weight":-0.6531},{"period":"6month","weight":-0.8244},{"period":"1year","weight":-0.8268},{"period":"ytd","weight":-0.6318}],"compareEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":-0.0698},{"period":"3month","weight":-0.0615},{"period":"6month","weight":0.0102},{"period":"1year","weight":0.1124},{"period":"ytd","weight":-0.0323}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.22291},{"month":2,"riseRate":0.4,"avgChangeRate":-0.005308},{"month":3,"riseRate":0.4,"avgChangeRate":0.155595},{"month":4,"riseRate":0,"avgChangeRate":-0.140893},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000114},{"month":6,"riseRate":0.5,"avgChangeRate":0.047361},{"month":7,"riseRate":0.25,"avgChangeRate":-0.006548},{"month":8,"riseRate":0.2,"avgChangeRate":0.036393},{"month":9,"riseRate":0,"avgChangeRate":-0.135388},{"month":10,"riseRate":0,"avgChangeRate":-0.227258},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05305},{"month":12,"riseRate":0.4,"avgChangeRate":-0.09901}],"exchange":"NASDAQ","name":"Inozyme Pharma","nameEN":"Inozyme Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inozyme Pharma,INZY,Inozyme Pharma股票,Inozyme Pharma股票老虎,Inozyme Pharma股票老虎国际,Inozyme Pharma行情,Inozyme Pharma股票行情,Inozyme Pharma股价,Inozyme Pharma股市,Inozyme Pharma股票价格,Inozyme Pharma股票交易,Inozyme Pharma股票购买,Inozyme Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}